Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

2024 ASCO® Annual Meeting Insights Hub

P. Johnson

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Follicular Lymphoma Management: What Is the New Order?

SOHO 2023 Eleventh Annual Meeting

B. Kahl

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

FDA Approval of Zanubrutinib in R/R FL: What You Need to Know

Christopher Flowers

Summary of Recent Advances in Follicular Lymphoma

Louisville Hematology Highlights

S. Gaballa

Emerging and Current Treatment for Hodgkin Lymphoma in 2024

Indy Hematology Review

S. Ansell

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

Tazemetostat in R/R FL: Impact of EZH2 Mutational Status on PFS

Bruce D. Cheson

ASCO® 2023 Insights: "SWOG S1826, a Randomized Study of Nivo-AVD vs.…

Insights from 2023 ASCO® Annual Meeting

A. Herrera